What is the ROCE (Return on Capital Employed) of BioCardia this year?
The ROCE of BioCardia is 7.26 undefined this year.
BioCardia ROCE 2024
BioCardia ROCE
7.26
Ticker
BCDA
ISIN
US09060U5074
WKN
A2PLXH
In 2024, BioCardia's return on capital employed (ROCE) was 7.26, a -398.49% increase from the -2.43 ROCE in the previous year.
BioCardia Aktienanalyse
What does BioCardia do?
BioCardia Inc is a medical technology company based in San Carlos, California, founded in 1994. They specialize in the development of medical devices used in the treatment of heart diseases. BioCardia has three main product lines: the Helix™ Biotherapy Platform, the Morph™ Transseptal Systems, and the CYPHER Select™ Balloon Catheter. The Helix™ Biotherapy Platform was developed to treat cardiovascular diseases using regenerative medicine. The system utilizes patient's own stem cells to repair damaged heart tissue and reduce the risk of heart attacks. This therapy method can significantly improve the quality of life and survival chances of patients with heart diseases. The Morph™ Transseptal Systems are used for minimally invasive removal of blood clots. They consist of a flexible guide wire and a catheter device that allows the doctor to remove the clot in the heart without performing an open surgery. This procedure is faster, safer, and less invasive than conventional methods. The CYPHER Select™ Balloon Catheter is used to open narrowed arteries in the heart. The balloon is inserted into the artery and inflated to break up the narrowing. Then, a medication is released to prevent the recurrence of the narrowing. This procedure is minimally invasive and enables faster recovery of patients. BioCardia is also involved in clinical research and collaborates closely with renowned institutions such as the Stanford University Medical Center. Through clinical studies, BioCardia collects important data on the efficacy and safety of its products. The results of these studies are published in medical journals and contribute to the advancement of medical practice. BioCardia's business model is based on the development and commercialization of innovative medical devices for the treatment of heart diseases. The company has built a portfolio of products and platforms that allow it to specialize in various areas of cardiovascular medicine. BioCardia also utilizes partnerships and collaborations to market its products and services. Overall, BioCardia is one of the leading companies in the field of medical devices for the treatment of heart diseases. With a portfolio of innovative products and a strong presence in medical research, BioCardia is well positioned to solidify its position as a market leader in the industry. BioCardia ist eines der beliebtesten Unternehmen auf Eulerpool.com.ROCE Details
Unraveling BioCardia's Return on Capital Employed (ROCE)
BioCardia's Return on Capital Employed (ROCE) is a financial metric that measures the company's profitability and efficiency with respect to the capital employed. It is calculated by dividing earnings before interest and tax (EBIT) by the employed capital. A higher ROCE indicates that the company is effectively utilizing its capital to generate profits.
Year-to-Year Comparison
Analyzing BioCardia's ROCE annually provides valuable insights into its efficiency in using its capital to generate profits. An increasing ROCE indicates improved profitability and operational efficiency, whereas a decrease might signal potential issues in capital utilization or business operations.
Impact on Investments
BioCardia's ROCE is a critical factor for investors and analysts for evaluating the company’s efficiency and profitability. A higher ROCE can make the company an attractive investment, as it often signifies that the firm is generating adequate profits from its employed capital.
Interpreting ROCE Fluctuations
Changes in BioCardia’s ROCE are attributed to variations in EBIT or the capital employed. These fluctuations offer insights into the company’s operational efficiency, financial performance, and strategic financial management, assisting investors in making informed investment decisions.
Frequently Asked Questions about BioCardia stock
How has the ROCE (Return on Capital Employed) of BioCardia developed compared to the previous year?
The ROCE of BioCardia has increased by -398.49% decreased compared to the previous year.
What does a high ROCE (Return on Capital Employed) mean for investors of BioCardia?
A high Return on Capital Employed (ROCE) indicates that BioCardia has efficient capital utilization and is able to achieve a higher return on its invested capital. This can be appealing to investors.
What does a low ROCE (Return on Capital Employed) mean for investors of BioCardia?
A low ROCE (Return on Capital Employed) can indicate that BioCardia has an inefficient utilization of its capital and may have difficulty in achieving a satisfactory return on its invested capital. This can be uncertain or unattractive for investors.
How does an increase in ROCE from BioCardia impact the company?
An increase in the ROCE of BioCardia can be an indicator of improved company efficiency and show that it is achieving higher profits in relation to its investments.
How does a reduction in the ROCE of BioCardia affect the company?
A decrease in ROCE of BioCardia can be an indicator of deteriorated efficiency of the company, indicating that it is generating lower profits in relation to its investments.
What are some factors that can influence the ROCE of BioCardia?
Some factors that can affect BioCardia's ROCE include efficiency in managing assets, profitability of investments, cost efficiency, and market conditions.
Why is the ROCE of BioCardia so important for investors?
The ROCE of BioCardia is important for investors as it is an indicator of the company's efficiency and shows how successful the company is in relation to its investments. A high ROCE can indicate strong financial performance of the company.
What strategic measures can BioCardia take to improve the ROCE?
To improve the ROCE, BioCardia can take measures such as increasing efficiency in asset management, optimizing investments, cost savings, and exploring new revenue sources. It is important for the company to conduct a thorough review of its operations to determine the best strategic actions to improve the ROCE.
How much dividend does BioCardia pay?
Over the past 12 months, BioCardia paid a dividend of . This corresponds to a dividend yield of about . For the coming 12 months, BioCardia is expected to pay a dividend of 0 USD.
What is the dividend yield of BioCardia?
The current dividend yield of BioCardia is .
When does BioCardia pay dividends?
BioCardia pays a quarterly dividend. This is distributed in the months of .
How secure is the dividend of BioCardia?
BioCardia paid dividends every year for the past 0 years.
What is the dividend of BioCardia?
For the upcoming 12 months, dividends amounting to 0 USD are expected. This corresponds to a dividend yield of 0 %.
In which sector is BioCardia located?
BioCardia is assigned to the 'Health' sector.
Wann musste ich die Aktien von BioCardia kaufen, um die vorherige Dividende zu erhalten?
To receive the latest dividend of BioCardia from 7/5/2024 amounting to 0 USD, you needed to have the stock in your portfolio before the ex-date on 7/5/2024.
When did BioCardia pay the last dividend?
The last dividend was paid out on 7/5/2024.
What was the dividend of BioCardia in the year 2023?
In the year 2023, BioCardia distributed 0 USD as dividends.
In which currency does BioCardia pay out the dividend?
The dividends of BioCardia are distributed in USD.
Stock savings plans offer an attractive way for investors to build wealth over the long term. One of the main advantages is the so-called cost-average effect: by regularly investing a fixed amount in stocks or stock funds, you automatically buy more shares when prices are low, and fewer when they are high. This can lead to a more favorable average price per share over time. In addition, stock savings plans allow small investors access to expensive stocks, as they can participate with small amounts. Regular investment also promotes a disciplined investment strategy and helps to avoid emotional decisions, such as impulsive buying or selling. Furthermore, investors benefit from the potential appreciation of the stocks as well as from dividend distributions, which can be reinvested, enhancing the compounding effect and thus the growth of the invested capital.
Andere Kennzahlen von BioCardia
Our stock analysis for BioCardia Revenue stock includes important financial indicators such as revenue, profit, P/E ratio, P/S ratio, EBIT, as well as information on dividends. We also assess aspects such as stocks, market capitalization, debt, equity, and liabilities of BioCardia Revenue. If you are looking for more detailed information on these topics, we offer comprehensive analyses on our subpages.
